Rigvir Group invites biotech, pharmaceutical companies and investors to cooperate in order to facilitate the development and availability of unique cancer virotherapy medicine worldwide.

Rigvir Group is a privately held company that brings together a number of enterprises that have been developing oncolytic virotherapy since 2002. Currently, the oncolytic virotherapy medicine has already been commercialised in 4 countries with access to more than 40 million people.

The medicine can now be recognized as the only one that offers a possibility to prevent metastases for early stage melanoma patients since no other effective and safe treatment is available in accordance with the international melanoma treatment guidelines (NCCN, ESMO).

The future perspective of the medicine is to become widely used as a monotherapy to prevent melanoma metastases in early stage patients and as synergistically advanced treatment combined with other immunotherapy drugs in late stage melanoma patients to achieve remarkable response rates.
That refers to both new and current markets of its registration.

The advantages of the medicine are its remarkable safety profile, stability and long-term clinical experience showing effectiveness and a unique ability to maintain a high life quality for patients.

The development potential of the medicine also refers to other indications and rare disease cases where virotherapy has already been used.

If you are an investor, a biotech or pharmaceutical company and want to receive a short presentation, please send a request letter with information about yourself to development@rigvir.com.